Back to results
US 10,370,445 B2Granted
Methods and agents for the diagnosis and treatment of hepatocellular carcinoma
AssigneeCircular Commitment Company
InventorsKuo-Jang Kao, Andrew T. Huang
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of diagnosing and methods of treating hepatocellular carcinoma in a subject. The invention also relates to antagonists of PLVAP proteins, such as antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising antagonists of PLVAP proteins. The invention further relates to humanized antibodies that specifically bind PLVAP protein.
Claims14
A method of diagnosing hepatocellular carcinoma (HCC) in a human subject, comprising:
- I) detecting the level of PLVAP protein in an isolated biological sample from the subject using an isolated polypeptide that specifically binds SEQ ID NO:
- 23;
- and
- II) determining that the level of the PLVAP gene product in the sample is increased relative to a control, wherein an increased level of the PLVAP protein in the sample relative to the control is indicative of HCC in the subject, thereby diagnosing HCC in the subject,
- wherein the isolated polypeptide is selected from:
- i) an isolated polypeptide comprising:
- 1) an antibody variable domain that comprises:
- a) a CDR1 consisting of SEQ ID NO:5;
- b) a CDR2 consisting of SEQ ID NO:6;
- and
- c) a CDR3 consisting of SEQ ID NO:7;
- and
- 2) an antibody variable domain that comprises:
- d) a CDR1 consisting of SEQ ID NO:10;
- e) a CDR2 consisting of SEQ ID NO:11;
- and
- f) a CDR3 consisting of SEQ ID NO:12;
- and
- ii) an isolated polypeptide comprising:
- 1) an antibody variable domain that comprises:
- a) a CDR1 consisting of SEQ ID NO:15;
- b) a CDR2 consisting of SEQ ID NO:16;
- and
- c) a CDR3 consisting of SEQ ID NO:17;
- and
- 2) an antibody variable domain that comprises:
- d) a CDR1 consisting of SEQ ID NO:20;
- e) a CDR2 consisting of SEQ ID NO:21;
- and
- f) a CDR3 consisting of SEQ ID NO:22.
27 more elements
An in vivo method of detecting hepatocellular carcinoma (HCC) in a subject, comprising:
- I) administering an isolated polypeptide that specifically binds SEQ ID NO:
- 23 to the subject by intra-arterial injection, wherein the isolated polypeptide comprises a radioisotope;
- II) obtaining an image of the liver of the subject;
- and
- III) detecting accumulation of the antibody in the liver of the subject, thereby detecting HCC in the subject,
- wherein the isolated polypeptide is selected from:
- i) an isolated polypeptide comprising:
- 1) an antibody variable domain that comprises:
- a) a CDR1 consisting of SEQ ID NO:5;
- b) a CDR2 consisting of SEQ ID NO:6;
- and
- c) a CDR3 consisting of SEQ ID NO:7;
- and
- 2) an antibody variable domain that comprises:
- d) a CDR1 consisting of SEQ ID NO:10;
- e) a CDR2 consisting of SEQ ID NO:11;
- and
- f) a CDR3 consisting of SEQ ID NO:12;
- and
- ii) an isolated polypeptide comprising:
- 1) an antibody variable domain that comprises:
- a) a CDR1 consisting of SEQ ID NO:15;
- b) a CDR2 consisting of SEQ ID NO:16;
- and
- c) a CDR3 consisting of SEQ ID NO:17;
- and
- 2) an antibody variable domain that comprises:
- d) a CDR1 consisting of SEQ ID NO:20;
- e) a CDR2 consisting of SEQ ID NO:21;
- and
- f) a CDR3 consisting of SEQ ID NO:22.
28 more elements
Dependencies are inferred from the claim text.